

Bevacizumab E2100

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



No QoL benefit



#### Serious and disabling adverse effects



#### Other adjustments



Only improved PFS mature data shows no OS advantage and no improved QoL



Bevacizumab E2100

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Therapeutic Indication: First-line treatment of adult patients with metastatic breast cancer

Experimental Arm: Bevacizumab + Paclitaxel

Control Arm: Paclitaxel



